Glp-1 Agonist And Sglt-2 Inhibitor Monotherapy Trial Results

ADVERTISEMENT

GLP-1 Agonist and SGLT-2 Inhibitor Monotherapy Trial Results
Drug
Class
HbA1c
Fasting BG
Weight change
CV Outcomes
FDA Approval
Reduction
Reduction
Semaglutide
GLP-1A
0.5 mg: 1.5%
0.5 mg: - 29 mg/dL
0.5 mg: - 10.1 lbs
Decreased risk of CV
Submitted;
1.0 mg: 1.8%
1.0 mg: - 43 mg/dL
1.0 mg: - 14.3 lbs
events by 26%
Awaiting FDA
Approval
Bydureon
GLP-1A
2 mg: 1.6%
2 mg: 25 mg/dL
2 mg: - 5 lbs
No statistically significant
Jan 2012
(exenatide ER)
change
Victoza
GLP-1A
1.2 mg: 0.8%
1.2 mg: 15 mg/dL
1.2 mg: - 4.6 lbs
FDA approved to reduce
Jan 2010
(liraglutide)
1.8 mg: 1.1%
1.8 mg: 26 mg/dL
1.8 mg: - 5.5 lbs
risk of MI, CVA & death
Trulicity
GLP-1A
.75 mg: 0.8%
.75 mg: 16 mg/dL
.75mg: - 2.9 lbs
Does not increase the
Sept 2014
(dulaglutide)
1.5 mg: 1.1%
1.5 mg: 27 mg/dL
1.5mg: - 4.1 lbs
chances of a CV event
Farxiga
SGLT2-I
5 mg: 1.2%
5 mcg: 42 mg/dL
5 mcg: - 5.7 lbs
Does not increase the
Jan 2014
(dapagliflozin)
10 mg: 1.5%
10 mcg: 46 mg/dL
10 mcg: - 6.0 lbs
chances of a CV event
Invokana
SGLT2-I
100 mg: 0.8%
100 mg: 27 mg/dL
100 mg: - 5.3 lbs
Significantly reduces risk
Mar 2013
(canagliflozin)
300 mg: 1.0%
300 mg: 35 mg/dL
300 mg: - 7.5 lbs
stroke, heart attack and
CV death
Jardiance
SGLT2-I
10 mg: 0.7%
10 mg: 19 mg/dL
10 mg: - 4.9 lbs
FDA approved to reduce
Aug 2014
(empagliflozin)
25 mg: 0.8%
25 mg: 25 mg/dL
25 mg: - 5.5 lbs
risk of CV death

ADVERTISEMENT

00 votes

Related Articles

Related forms

Related Categories

Parent category: Medical
Go